Atai Life Sciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagSimply Wall St • about 1 month ago
Atai Life Sciences ( NASDAQ:ATAI ) Full Year 2023 Results Key Financial Results Net loss: US$40.2m (loss narrowed by...
Share to Feed
Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato Initial BPL-003...
- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect in TRD patients, with 45% of patients in clinical remission at week 12 - 55% of patients achieved a clinical...
The Next Great Biotech Boom Has Arrived The Next Great Biotech Boom Has Arrived PR Newswire LONDON, March 19, 2024 FN Media Group Presents GlobalInvestmentDaily.com Market Commentary LONDON, March...
The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai's proprietary, optimized oral transmucosal formulation of DMTVLS-01 is being...
NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ( atai ), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ( atai or Company ) today announced that Anne Johnson, the Company's interim Chief Financial Officer since...
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder...
Strategic investment in Beckley Psytech reinforces atai's position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo...
EMP-01 (R-MDMA) was generally well-tolerated and treatment-related adverse events (AEs) were as expectedThe PK profile of EMP-01 was dose-proportional, and a range of exploratory pharmacodynamic (PD...